Clinical trials: Pancreatic Neuroendocine Neoplasms (pNETs)
Neoplasms, Breast Neoplasms
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Dose escalation part: to determine the highest dose of alpelisib administered on a daily basis when given in combination with daily everolimus or in combination with daily everolimus and exemestane.
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Trial name
- NCT02077933
- Testing
- alpelisib, everolimus, exemestane
- Where
- 22 sites in United States, France and 7 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals